title: [The efficiency of combined therapy of herpes virus infection in HIV infected patients].
abstract: The target of the case study was to investigate the efficiency of an alternative combined therapy scheme of herpes simplex infections versus the routine therapy by acyclovir or famvir as applicable to HIV-infected patients. leukinferon was shown to induce the antoherpetic acyclovir efficiency. The use of the latter concurrently with cycloferon for the treatment of infections provoked by herpes simple virus-1 (HSV-1) and HSV-2 in HIV-infected patients prolongs the remission period in case of the above opportunistic infections. The leukinferon anti-herpetic efficiency is, obviously, related with the phagocytosis stimulation and with its positive influence exerted on hemopoiesis. The combined therapy can be stated to be most effective in HIV, clinical stages B1 and 2.
authors.forename: M N
authors.initials: MN
authors.lastname: Papuashvili
authors.forename: M Iu
authors.initials: MIu
authors.lastname: Shchelkanov
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000150:complications / Q000188:drug therapy*; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D015497:HIV-1; D006561:Herpes Simplex / Q000150:complications / Q000188:drug therapy*; D018259:Herpesvirus 1, Human; D018258:Herpesvirus 2, Human; D006801:Humans; D007275:Injections, Intravenous; D007369:Interferon Inducers / Q000627:therapeutic use*; D018655:Lymphocyte Count; D008297:Male; D010455:Peptides / Q000627:therapeutic use*; D016176:T-Lymphocyte Subsets / Q000276:immunology; D013949:Thymus Extracts / Q000627:therapeutic use*
chemical_list: D000276:Adjuvants, Immunologic; D000998:Antiviral Agents; D007369:Interferon Inducers; D010455:Peptides; D013949:Thymus Extracts; C036191:T-activin